ADDITIONAL INFORMATION CONTINUED EMPLOYEE REMUNERATION The number of employees, not being directors of the Company, who received remuneration and benefits in their capacity as employees totalling NZ $100,000 or more during the year, shown in bands denominated in Australian dollars, was as follows: Excluding share based payments 2023 $’000 2022 $’000 $150,000 – $159,999 – 1 $190,000 – $199,999 1 1 $200,000 – $209,999 1 – $220,000 – $229,999 1 – $240,000 – $249,999 – 2 $270,000 – $279,999 – 1 $280,000 – $289,999 1 – $300,000 – $309,999 1 1 $480,000 – $489,999 1 – $510,000 – $519,999 1 – $640,000 – $649,999 1 – Including share based payments 2023 $’000 2022 $’000 $150,000 – $159,999 – 1 $190,000 – $199,999 1 – $200,000 – $209,999 1 – $220,000 – $229,999 1 – $340,000 – $349,999 – 1 $360,000 – $369,999 – 1 $390,000 – $399,999 – 1 $400,000 – $409,999 – 1 $510,000 – $519,999 1 – $590,000 – $599,999 1 – $630,000 – $639,999 1 – $640,000 – $649,999 – 1 $650,000 – $659,999 1 – $1,200,000 – $1,209,999 1 – AUDITORS Grant Thornton New Zealand Audit Limited (‘Grant Thornton’) is the independent auditor of the Company. Audit fees in relation to the annual and interim financial statements were $98,963 (2022: $70,214). Grant Thornton did not receive any other fees in relation to other financial advice and services. No amounts were payable to an auditor by subsidiary companies in 2023 or 2022. Neuren Pharmaceuticals Limited Annual Report 2023 55
RkJQdWJsaXNoZXIy MjE2NDg3